Phase 3 study of IPX066 initiated for Parkinson’s disease

Impax Pharmaceuticals announced it has commenced a Phase 3 trial of IPX066 to treat Parkinson’s disease (PD) based on encouraging interim data collected from its Phase 2 study in PD patients. This study, known as APEX-PD, will be the first of two Phase 3 studies and will include Parkinson’s disease patients with mild symptoms of PD. Impax is planning to commence a second Phase 3 trial of IPX066 in patients with advanced PD patients later in 2009 or early 2010.

IPX066 is an investigational extended-release carbidopa-levodopa product designed to produce a fast and sustained concentration of levodopa, potentially improving PD clinical symptom management.

For more information call (215) 289-2220 or visit